Introduction: The mTOR pathway is involved in the regulation of a wide repertoire of cellular functions in the brain and its dysregulation is emerging as a leitmotif in a large number of neurological disorders. In AD, altered mTOR signaling contributes to the inhibition of autophagy deposition of Aβ and tau aggregates and to the alteration of several neuronal metabolic pathways. Areas covered: In this review, we report all the current findings on the use of mTOR inhibitors (rapamycin, rapalogues) in the treatment of AD. These results support the role of mTOR inhibitors as potential therapeutic agents able to reduce AD hallmarks and recover cognitive performances. Expert commentary: Despite mTOR inhibitors appearing to be ideal compounds to counteract AD, further studies are needed in order to gain knowledge on the involvement of aberrant mTOR in AD, and to standardize a valuable therapeutic approach that can be translated to humans.

Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies / Tramutola, Antonella; Lanzillotta, Chiara; DI DOMENICO, Fabio. - In: EXPERT REVIEW OF NEUROTHERAPEUTICS. - ISSN 1473-7175. - 17:1(2017), pp. 33-45. [10.1080/14737175.2017.1244482]

Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies

TRAMUTOLA, ANTONELLA;LANZILLOTTA, CHIARA;DI DOMENICO, FABIO
2017

Abstract

Introduction: The mTOR pathway is involved in the regulation of a wide repertoire of cellular functions in the brain and its dysregulation is emerging as a leitmotif in a large number of neurological disorders. In AD, altered mTOR signaling contributes to the inhibition of autophagy deposition of Aβ and tau aggregates and to the alteration of several neuronal metabolic pathways. Areas covered: In this review, we report all the current findings on the use of mTOR inhibitors (rapamycin, rapalogues) in the treatment of AD. These results support the role of mTOR inhibitors as potential therapeutic agents able to reduce AD hallmarks and recover cognitive performances. Expert commentary: Despite mTOR inhibitors appearing to be ideal compounds to counteract AD, further studies are needed in order to gain knowledge on the involvement of aberrant mTOR in AD, and to standardize a valuable therapeutic approach that can be translated to humans.
File allegati a questo prodotto
File Dimensione Formato  
Tramutola_Targeting mTOR_2017

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 949.09 kB
Formato Adobe PDF
949.09 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/930567
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 13
social impact